1194-74-7 Usage
Description
4(1H)-Pyrimidinone, 6-hydroxy-2,5-dimethyl(9CI), also known as 2,5-Dimethylpyrimidine-4,6-diol, is a chemical compound belonging to the pyrimidine family. It features a pyrimidinone core with hydroxy and methyl groups at the 6th and 2nd, 5th positions, respectively. 4(1H)-Pyrimidinone, 6-hydroxy-2,5-dimethyl(9CI) is recognized for its potential role in the synthesis of pharmaceutically active dimethylpyrimidines.
Uses
Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, 6-hydroxy-2,5-dimethyl(9CI) is utilized as a chemical reagent for the synthesis of pharmaceutically active dimethylpyrimidines. These synthesized compounds hold promise for various therapeutic applications, given their potential to exhibit biological activities beneficial in treating a range of medical conditions. The reagent aids in the development of new drugs by providing a key structural component in the creation of these active pharmaceutical ingredients.
Check Digit Verification of cas no
The CAS Registry Mumber 1194-74-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,9 and 4 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1194-74:
(6*1)+(5*1)+(4*9)+(3*4)+(2*7)+(1*4)=77
77 % 10 = 7
So 1194-74-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O2/c1-3-5(9)7-4(2)8-6(3)10/h1-2H3,(H2,7,8,9,10)
1194-74-7Relevant articles and documents
-
Hasapis,MacLeod
, p. 2087 (1979)
-
Pyrimidine Derivatives Which Are Antagonists Of Vitronectin Receptor
-
Page/Page column 14, (2010/11/30)
A subject of the invention is the compounds of formula (I); in which R1, R2, R3, R4 and R have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.
PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF
-
Page/Page column 173, (2008/06/13)
The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.